<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811875</url>
  </required_header>
  <id_info>
    <org_study_id>8VWF07</org_study_id>
    <nct_id>NCT01811875</nct_id>
  </id_info>
  <brief_title>Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A</brief_title>
  <official_title>Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Products Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Products Laboratory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess post-marketing immunogenicity of Optivate® by monitoring plasma&#xD;
      inhibitor levels for at least 100 Exposure Days (EDs) for each subject.&#xD;
&#xD;
      Secondary objectives: To assess efficacy and tolerability by monitoring FVIII recovery and&#xD;
      adverse events&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary efficacy endpoint is to assess immunogenicity of Optivate® by monitoring plasma&#xD;
      inhibitor level for at least 100 EDs for each subject.&#xD;
&#xD;
      FVIII inhibitor evaluation FVIII inhibitor screen data will be listed. FVIII quantitative&#xD;
      inhibitor results will be listed. Shift tables will present the number of subjects with&#xD;
      positive (≥ 0.6 BU) and negative (&lt; 0.6 BU) results and those for whom the results change&#xD;
      during the study. The number of exposure days until development of inhibitors will be&#xD;
      summarised.&#xD;
&#xD;
      For the secondary endpoints: Descriptive statistics will be presented on the number of&#xD;
      recoveries at each timepoint and for each subject. These will be presented for each visit and&#xD;
      for each subject and then for each batch of FVIII/ Optivate® used. All the AE data (from CRF&#xD;
      and study diary) will be pooled together and reported in terms of the type, duration,&#xD;
      treatment and/or severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study no longer required as Optivate German license expired in Sep-2017.&#xD;
  </why_stopped>
  <start_date type="Actual">November 21, 2014</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Did Not Develop Inhibitors to FVIII (&lt;0.6BU)</measure>
    <time_frame>At least 100 Exposure Days for each subject. Subjects will attend 5 visits over a period of up to 12 months</time_frame>
    <description>FVIII inhibitor status at any of the study visits was measured by a Nijmegen Bethesda assay and inhibitor screens. A result of ≥ 0.6 BU confirmed that the subject had developed inhibitors to FVIII. If this occurred, the test was repeated on a separate sample; if both tests were confirmed to be ≥ 0.6 BU, this was to be reported by the Investigator as a serious adverse event (SAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery With Prior FVIII Concentrate (Screening Visit) Versus Recovery With First Dose With Optivate® (Visit 1) for the Protocol Population.</measure>
    <time_frame>Screening and Visit 1 (up to 4 weeks)</time_frame>
    <description>Recovery with prior FVIII concentrate (Screening Visit) versus recovery with first dose with Optivate® (Visit 1) for the protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optivate® Recovery Across Visits 1 to 4 for the Protocol Population.</measure>
    <time_frame>Visits 1 to 4 (Up to 100 Optivate exposure days)</time_frame>
    <description>A recovery assessment was conducted at each study visit. Recovery assessments were only conducted after a 3-day washout period and when the subject was not actively bleeding.&#xD;
At the Screening Visit, subjects who had completed a 3-day washout period and were not actively bleeding were dosed with 30 IU/kg of their prior FVIII concentrate. The dose was measured to the nearest 0.1 mL. Blood samples for the recovery assessment were to be collected at the following time points:&#xD;
Predose&#xD;
15 minutes postinfusion (±5 minutes).&#xD;
30 minutes postinfusion (±5 minutes).&#xD;
1 hour postinfusion (±10 minutes). Actual times of sample collection were to be recorded in the CRF&#xD;
At visits 1, 2, 3 and 4 subjects were dosed with 30 IU/kg of Optivate and blood samples for recovery assessments were taken at the same timepoints as specified above. An ANOVA model (analysis of variance) was used to calculate the adjusted mean for recovery across visits 1 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optivate® Therapy to Treat Breakthrough Bleeds Per Subject Per Year in the Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Optivate® therapy to treat number of breakthrough bleeds per subject per year in the protocol population over a period of 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Number of Exposure Days for Each Subject Per Year/Subject in the Per Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Overall consumption of Optivate®: Number of exposure days for each subject per year/subject in the per protocol population over a period of 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject for Prophylactic Use.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject for prophylactic use over a period of 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject to Treat a Bleed in the Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject to treat a bleed in the protocol population over a period of 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Total Number of Infusions for Prophylactic Use Per Subject in the Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Overall consumption of Optivate®: Total number of infusions for prophylactic use per subject in the protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Total Number of Infusions to Treat a Bleed Per Subject in the Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Total number of infusions to treat a bleed per subject in the protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Consumption of Optivate®: Overall Mean Dose in IU/kg of Optivate® Per Subject/Year for Prophylactic Use in the Protocol Population.</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Overall consumption of Optivate®: Overall mean dose in IU/kg of Optivate® per subject/year for prophylactic use in the protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events (Non-serious) in the Safety Population</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Treatment emergent adverse events (non-serious) in the safety population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events (Serious) in Safety Population</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Treatment emergent adverse events (serious) in safety population over a period of 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Inhibitor Development in Safety Population (Measured by ≥0.6 Bethesda Units)</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Inhibitor Development: Positive FVIII inhibitor status in safety population measured by ≥0.6 Bethesda units (this was a safety measurement but was assessed as a primary efficacy endpoint).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Optivate 500IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optivate 500IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Optivate 500IU</intervention_name>
    <arm_group_label>Optivate 500IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent or, if less than 18 years of age written assent (where&#xD;
             possible) and their parent/guardian's written informed consent.&#xD;
&#xD;
          -  Severe haemophilia A (&lt; 1%# FVIII:C).&#xD;
&#xD;
          -  Previously Treated Patients (PTPs) with &gt; 150 exposure days on prior Factor VIII&#xD;
             therapy (of which at least the last 50 EDs or 2 years treatment can be confirmed by&#xD;
             way of subject records).&#xD;
&#xD;
          -  Immunocompetent with CD4 count &gt; 200 / µl.&#xD;
&#xD;
          -  HIV negative or a viral load &lt; 200 particles / µl.&#xD;
&#xD;
               -  subjects suffering from severe haemophilia A (&lt;2%) may be enrolled, but only&#xD;
                  after approval by BPL. Subjects with a Factor VIII of &lt;2% may not constitute more&#xD;
                  than 50% of the total patient population. A separate statistical evaluation will&#xD;
                  be conducted for the &lt;1% and &lt;2% populations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • History of inhibitor development to FVIII or a positive result on the Nijmegen&#xD;
             Bethesda at screening (quantitative result of &gt; 0.6 BU) prior to the administration of&#xD;
             Optivate®.&#xD;
&#xD;
               -  Known or suspected hypersensitivity to the investigational medicinal product or&#xD;
                  its excipients.&#xD;
&#xD;
               -  Clinically significant liver disease, renal disease, or coagulopathy other than&#xD;
                  haemophilia A.&#xD;
&#xD;
               -  History of unreliability or non cooperation (including not being able to complete&#xD;
                  the study diary).&#xD;
&#xD;
               -  Participating in, or have taken part in another trial within the last 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Wolford</last_name>
    <role>Study Director</role>
    <affiliation>Bio Products Laboratory</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion BIOS</name>
      <address>
        <city>Barranquilla</city>
        <zip>80-216</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital general de Medellin</name>
      <address>
        <city>Medellin</city>
        <zip>32-102</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HZRM Haemophilia Centre Rhine Main</name>
      <address>
        <city>Darmstadt</city>
        <state>Mörfelden-Walldorf</state>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <results_first_submitted>February 28, 2018</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01811875/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 21, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01811875/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seven patients were enrolled. One patient in Germany; 4 patients in Colombia and 2 patients in Poland.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Optivate 500IU</title>
          <description>Optivate 500IU&#xD;
Optivate 500IU</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Optivate 500IU</title>
          <description>Optivate 500IU&#xD;
Optivate 500IU</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Did Not Develop Inhibitors to FVIII (&lt;0.6BU)</title>
        <description>FVIII inhibitor status at any of the study visits was measured by a Nijmegen Bethesda assay and inhibitor screens. A result of ≥ 0.6 BU confirmed that the subject had developed inhibitors to FVIII. If this occurred, the test was repeated on a separate sample; if both tests were confirmed to be ≥ 0.6 BU, this was to be reported by the Investigator as a serious adverse event (SAE).</description>
        <time_frame>At least 100 Exposure Days for each subject. Subjects will attend 5 visits over a period of up to 12 months</time_frame>
        <population>Patients who completed at least 100 exposure days to Optivate.</population>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Did Not Develop Inhibitors to FVIII (&lt;0.6BU)</title>
          <description>FVIII inhibitor status at any of the study visits was measured by a Nijmegen Bethesda assay and inhibitor screens. A result of ≥ 0.6 BU confirmed that the subject had developed inhibitors to FVIII. If this occurred, the test was repeated on a separate sample; if both tests were confirmed to be ≥ 0.6 BU, this was to be reported by the Investigator as a serious adverse event (SAE).</description>
          <population>Patients who completed at least 100 exposure days to Optivate.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recovery With Prior FVIII Concentrate (Screening Visit) Versus Recovery With First Dose With Optivate® (Visit 1) for the Protocol Population.</title>
        <description>Recovery with prior FVIII concentrate (Screening Visit) versus recovery with first dose with Optivate® (Visit 1) for the protocol population.</description>
        <time_frame>Screening and Visit 1 (up to 4 weeks)</time_frame>
        <population>Recovery with prior FVIII concentrate (Screening Visit) versus first dose with Optivate® (Visit 1) for the protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery With Prior FVIII Concentrate (Screening Visit) Versus Recovery With First Dose With Optivate® (Visit 1) for the Protocol Population.</title>
          <description>Recovery with prior FVIII concentrate (Screening Visit) versus recovery with first dose with Optivate® (Visit 1) for the protocol population.</description>
          <population>Recovery with prior FVIII concentrate (Screening Visit) versus first dose with Optivate® (Visit 1) for the protocol population.</population>
          <units>IU/dL per IU/kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.87" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optivate® Recovery Across Visits 1 to 4 for the Protocol Population.</title>
        <description>A recovery assessment was conducted at each study visit. Recovery assessments were only conducted after a 3-day washout period and when the subject was not actively bleeding.&#xD;
At the Screening Visit, subjects who had completed a 3-day washout period and were not actively bleeding were dosed with 30 IU/kg of their prior FVIII concentrate. The dose was measured to the nearest 0.1 mL. Blood samples for the recovery assessment were to be collected at the following time points:&#xD;
Predose&#xD;
15 minutes postinfusion (±5 minutes).&#xD;
30 minutes postinfusion (±5 minutes).&#xD;
1 hour postinfusion (±10 minutes). Actual times of sample collection were to be recorded in the CRF&#xD;
At visits 1, 2, 3 and 4 subjects were dosed with 30 IU/kg of Optivate and blood samples for recovery assessments were taken at the same timepoints as specified above. An ANOVA model (analysis of variance) was used to calculate the adjusted mean for recovery across visits 1 to 4.</description>
        <time_frame>Visits 1 to 4 (Up to 100 Optivate exposure days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Optivate® Recovery Across Visits 1 to 4 for the Protocol Population.</title>
          <description>A recovery assessment was conducted at each study visit. Recovery assessments were only conducted after a 3-day washout period and when the subject was not actively bleeding.&#xD;
At the Screening Visit, subjects who had completed a 3-day washout period and were not actively bleeding were dosed with 30 IU/kg of their prior FVIII concentrate. The dose was measured to the nearest 0.1 mL. Blood samples for the recovery assessment were to be collected at the following time points:&#xD;
Predose&#xD;
15 minutes postinfusion (±5 minutes).&#xD;
30 minutes postinfusion (±5 minutes).&#xD;
1 hour postinfusion (±10 minutes). Actual times of sample collection were to be recorded in the CRF&#xD;
At visits 1, 2, 3 and 4 subjects were dosed with 30 IU/kg of Optivate and blood samples for recovery assessments were taken at the same timepoints as specified above. An ANOVA model (analysis of variance) was used to calculate the adjusted mean for recovery across visits 1 to 4.</description>
          <units>IU/dL per IU/kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-1.72" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Optivate® Therapy to Treat Breakthrough Bleeds Per Subject Per Year in the Protocol Population.</title>
        <description>Optivate® therapy to treat number of breakthrough bleeds per subject per year in the protocol population over a period of 12 months.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Optivate® Therapy to Treat Breakthrough Bleeds Per Subject Per Year in the Protocol Population.</title>
          <description>Optivate® therapy to treat number of breakthrough bleeds per subject per year in the protocol population over a period of 12 months.</description>
          <units>Bleeds per subject per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" spread="2.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Number of Exposure Days for Each Subject Per Year/Subject in the Per Protocol Population.</title>
        <description>Overall consumption of Optivate®: Number of exposure days for each subject per year/subject in the per protocol population over a period of 12 months.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Number of Exposure Days for Each Subject Per Year/Subject in the Per Protocol Population.</title>
          <description>Overall consumption of Optivate®: Number of exposure days for each subject per year/subject in the per protocol population over a period of 12 months.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.2" spread="18.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject for Prophylactic Use.</title>
        <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject for prophylactic use over a period of 12 months.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject for Prophylactic Use.</title>
          <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject for prophylactic use over a period of 12 months.</description>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3639.97" spread="993.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject to Treat a Bleed in the Protocol Population.</title>
        <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject to treat a bleed in the protocol population over a period of 12 months.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Total Dose in IU/kg of Optivate® Per Subject to Treat a Bleed in the Protocol Population.</title>
          <description>Overall consumption of Optivate®: Total dose in IU/kg of Optivate® per subject to treat a bleed in the protocol population over a period of 12 months.</description>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.72" spread="117.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Total Number of Infusions for Prophylactic Use Per Subject in the Protocol Population.</title>
        <description>Overall consumption of Optivate®: Total number of infusions for prophylactic use per subject in the protocol population.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Total Number of Infusions for Prophylactic Use Per Subject in the Protocol Population.</title>
          <description>Overall consumption of Optivate®: Total number of infusions for prophylactic use per subject in the protocol population.</description>
          <units>Infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.8" spread="17.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Total Number of Infusions to Treat a Bleed Per Subject in the Protocol Population.</title>
        <description>Total number of infusions to treat a bleed per subject in the protocol population.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Total Number of Infusions to Treat a Bleed Per Subject in the Protocol Population.</title>
          <description>Total number of infusions to treat a bleed per subject in the protocol population.</description>
          <units>Infusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Consumption of Optivate®: Overall Mean Dose in IU/kg of Optivate® Per Subject/Year for Prophylactic Use in the Protocol Population.</title>
        <description>Overall consumption of Optivate®: Overall mean dose in IU/kg of Optivate® per subject/year for prophylactic use in the protocol population.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Consumption of Optivate®: Overall Mean Dose in IU/kg of Optivate® Per Subject/Year for Prophylactic Use in the Protocol Population.</title>
          <description>Overall consumption of Optivate®: Overall mean dose in IU/kg of Optivate® per subject/year for prophylactic use in the protocol population.</description>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3890.02" spread="1033.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Emergent Adverse Events (Non-serious) in the Safety Population</title>
        <description>Treatment emergent adverse events (non-serious) in the safety population.</description>
        <time_frame>Over a period of 12 months</time_frame>
        <population>A total of 3 patients experienced treatment emergent adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Emergent Adverse Events (Non-serious) in the Safety Population</title>
          <description>Treatment emergent adverse events (non-serious) in the safety population.</description>
          <population>A total of 3 patients experienced treatment emergent adverse events.</population>
          <units>treatment emergent events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Emergent Adverse Events (Serious) in Safety Population</title>
        <description>Treatment emergent adverse events (serious) in safety population over a period of 12 months</description>
        <time_frame>Over a period of 12 months</time_frame>
        <population>One patient experienced a treatment emergent adverse event (serious).</population>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Emergent Adverse Events (Serious) in Safety Population</title>
          <description>Treatment emergent adverse events (serious) in safety population over a period of 12 months</description>
          <population>One patient experienced a treatment emergent adverse event (serious).</population>
          <units>treatment emergent events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Inhibitor Development in Safety Population (Measured by ≥0.6 Bethesda Units)</title>
        <description>Inhibitor Development: Positive FVIII inhibitor status in safety population measured by ≥0.6 Bethesda units (this was a safety measurement but was assessed as a primary efficacy endpoint).</description>
        <time_frame>Over a period of 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optivate 500IU</title>
            <description>Optivate 500IU&#xD;
Optivate 500IU</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Inhibitor Development in Safety Population (Measured by ≥0.6 Bethesda Units)</title>
          <description>Inhibitor Development: Positive FVIII inhibitor status in safety population measured by ≥0.6 Bethesda units (this was a safety measurement but was assessed as a primary efficacy endpoint).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over a period of 12 months</time_frame>
      <desc>Patients had an electronic diary where they could enter any adverse events they experienced in between study visits. Adverse events were assessed at each study visit otherwise. The 9 adverse events (non-serious) recorded include non-treatment emergent and treatment emergent events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Optivate 500IU</title>
          <description>Optivate 500IU&#xD;
Optivate 500IU</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fatal road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GENERAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COMMON COLD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE TRAUMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE TRAUMA LEFT HAND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HEMARTHROSIS OF RIGHT ELBOW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>JOINT PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>HEMARTHROSIS OF RIGHT KNEE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>European Medical Affairs Lead</name_or_title>
      <organization>Bio Products Laboratory Ltd</organization>
      <phone>+44 20 8957 2200</phone>
      <email>medinfo@bpl.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

